Novel and Emerging Targeted Therapies of Colorectal Cancer

被引：4
作者：
Finnberg, Niklas [1 ,2 ]
Gokare, Prashanth
El-Deiry, Wafik S.
机构：
[1] Fox Chase Canc Ctr, Lab Translat Oncol & Expt Canc Therapeut, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Mol Therapeut Program, Philadelphia, PA 19111 USA
来源：
CURRENT CLINICAL PHARMACOLOGY | 2015年 / 10卷 / 04期
关键词：
Clinical; colorectal cancer; DPYD; RAS; targeted therapy; TRAIL;
D O I：
10.2174/1574884710666151020095911
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the United States. Current targeted strategies offer limited clinical benefits and the overall survival rate for CRC remains low. Improved understanding of the molecular changes associated with CRC that control growth factor signaling and evasion of cell death allow for the development of improved targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
引用
收藏
页码：279 / 298
页数：20
相关论文
共 242 条
[11]   Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines [J].
Arnold, CN ;
Goel, A ;
Boland, CR .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (01) :66-73
[12]   Targeting the extrinsic apoptosis pathway in cancer [J].
Ashkenazi, Avi .
CYTOKINE & GROWTH FACTOR REVIEWS, 2008, 19 (3-4) :325-331
[13]   MAP kinase pathways: The first twenty years [J].
Avruch, Joseph .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2007, 1773 (08) :1150-1160
[14]   Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase [J].
Baker, SD ;
Khor, SP ;
Adjei, AA ;
Doucette, M ;
Spector, T ;
Donehower, RC ;
Grochow, LB ;
Sartorius, SE ;
Noe, DA ;
Hohneker, JA ;
Rowinsky, EK .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3085-3096
[15]   Pharmacology of fluorinated pyrimidines: Eniluracil [J].
Baker, SD .
INVESTIGATIONAL NEW DRUGS, 2000, 18 (04) :373-381
[16]   Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies [J].
Barton, Sarah ;
Starling, Naureen ;
Swanton, Charles .
CURRENT CANCER DRUG TARGETS, 2010, 10 (08) :799-812
[17]   A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors [J].
Baselga, J. ;
De Jonge, M. J. ;
Rodon, J. ;
Burris, H. A., III ;
Birle, D. C. ;
De Buck, S. S. ;
Demanse, D. ;
Ru, Q. C. ;
Goldbrunner, M. ;
Bendell, J. C. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[18]  
Beaven AW, 2006, ONCOLOGY WILLISTON P, V20, P9
[19]  
Beaven AW, 2006, ONCOLOGY WILLISTON P, V20, P73
[20]   A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens [J].
Bennouna, Jaafar ;
Lang, Istvan ;
Valladares-Ayerbes, Manuel ;
Boer, Katalin ;
Adenis, Antoine ;
Escudero, Pilar ;
Kim, Tae-You ;
Pover, Gillian M. ;
Morris, Clive D. ;
Douillard, Jean-Yves .
INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) :1021-1028
12345678910